Amicus Therapeutics Inc.
Annual Meeting Voting Results Announced by Amicus Therapeutics, Inc.
Summary
Amicus Therapeutics, Inc. announced the results of the 2025 Annual Meeting of Stockholders held on June 5, 2025. Stockholders elected four new Class III directors, approved the 2025 Equity Incentive Plan, ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the compensation of named executive officers on an advisory basis. The financial statements and related exhibits were also furnished.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement